
Development and verification of an immune‐related gene pairs prognostic signature in ovarian cancer
Author(s) -
Zhang Bao,
Nie Xiaocui,
Miao Xinxin,
Wang Shuo,
Li Jing,
Wang Shengke
Publication year - 2021
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.16327
Subject(s) - ovarian cancer , oncology , lasso (programming language) , proportional hazards model , gene signature , immunotherapy , medicine , immune system , gene , biology , cancer , bioinformatics , gene expression , immunology , genetics , computer science , world wide web
Ovarian cancer (OV) is the most common gynaecological cancer worldwide. Immunotherapy has recently been proven to be an effective treatment strategy. The work here attempts to produce a prognostic immune‐related gene pair (IRGP) signature to estimate OV patient survival. The Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases provided the genetic expression profiles and clinical data of OV patients. Based on the InnateDB database and the least absolute shrinkage and selection operator (LASSO) regression model, we first identified a 17‐IRGP signature associated with survival. The average area under the curve (AUC) values of the training, validation, and all TCGA sets were 0.869, 0.712, and 0.778, respectively. The 17‐IRGP signature noticeably split patients into high‐ and low‐risk groups with different prognostic outcomes. As suggested by a functional study, some biological pathways, including the Toll‐like receptor and chemokine signalling pathways, were significantly negatively correlated with risk scores; however, pathways such as the p53 and apoptosis signalling pathways had a positive correlation. Moreover, tumour stage III, IV, grade G1/G2, and G3/G4 samples had significant differences in risk scores. In conclusion, an effective 17‐IRGP signature was produced to predict prognostic outcomes in OV, providing new insights into immunological biomarkers.